JP Morgan Chase
IKT icon

JP Morgan Chase’s Inhibikase Therapeutics IKT Stock Holding History

JP Morgan Chase’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Sell
316,574
-11,944
-4% -$21.4K ﹤0.01% 4966
2026
Q1 		$519K Buy
328,518
+303,669
+1,222% +$539K ﹤0.01% 4978
2025
Q4 		$50.9K Sell
24,849
-25,088
-50% -$39.9K ﹤0.01% 6218
2025
Q3 		$80.9K Buy
49,937
+21,358
+75% +$37K ﹤0.01% 6023
2025
Q2 		$55.7K Buy
+28,579
New +$56K ﹤0.01% 5880
2023
Q4 		– Sell
-5
Closed -$7 – 7679
2023
Q3 		$7 Buy
5
+3
+150% +$7 ﹤0.01% 7331
2023
Q2 		$7 Buy
+2
New +$7 ﹤0.01% 6828

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's IKT Position: Q2 2026 in Review

JP Morgan Chase reduced its Inhibikase Therapeutics (IKT) stake by 3.6% in Q2 2026, selling an estimated $21.4K and leaving 316,574 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #4966.

JP Morgan Chase first reported a position in IKT in Q2 2023 and has held it in 7 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • JP Morgan Chase held 316,574 shares of Inhibikase Therapeutics worth $611K as of Q2 2026.
  • JP Morgan Chase sold 11,944 Inhibikase Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Inhibikase Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4966 holding.
  • JP Morgan Chase first reported a position in Inhibikase Therapeutics in Q2 2023 and has held it in 7 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.